News
November 11, 2021 · 6 mins read
Innovative CNS Startup Ignis Therapeutics Sets New Record for 2021 Biopharma Series A Financing in China. Partners with SK Biopharmaceuticals to Bring Innovative Therapies to Patients.
Reading
December 9, 2025 · 4 mins read
Ignis Therapeutics' Solriamfetol Hydrochloride Tablets (翼朗清®) officially approved in China
Reading
December 9, 2025 · 6 mins read
New Anti-Seizure Medication cenobamate Tablets（翼弗瑞®）Officially Approved in China, Ushering in a New Chapter for Epilepsy Treatment
Reading
November 10, 2025 · 4 mins read
Ignis Therapeutics Announces Publication of Phase III Trial for Solriamfetol in Treating OSA-EDS in China
Reading
October 24, 2025 · 4 mins read
Ignis Therapeutics and China Association Against Epilepsy Forge Strategic Partnership to Advance Seizure-Free Futures
Reading
September 29, 2025 · 4 mins read
Cenobamate Recommended in Chinese Expert Consensus! Dual-Mechanism Sodium Channel Blocker Offers New Option for Focal Seizures Patients
Reading
December 10, 2024 · 2 mins read
Ignis Announces CDE Acceptance of New Drug Applications for Two Innovative CNS Therapies
Reading
January 12, 2024 · 2 mins read
$160 Million Total Investment! Today, Ignis Therapeutics Commences Construction.
Reading
November 1, 2023 · 1 min read
Center for Excellence in Molecular Cell Science, CAS, and Ignis Therapeutics Forge Collaboration Agreement.
Reading
January 26, 2022 · 2 mins read
Ignis Therapeutics Licenses NeuroSigma eTNS Technology for ADHD in a Significant China Licensing Transaction.
Reading
"We anticipate collaborating with partners to unlock the full potential of innovations and jointly forge a blueprint for a vibrant, healthier future."
Address
46F, BM InterContinental Business Center, No.100 Yutong Road, Jing’an District, Shanghai, China
